University of Wisconsin–Madison

Stereo-Selectivity in Drug Metabolism

When: October 5, 2017 11:00am CST

There are few aspects of drug metabolism and metabolite profiling more essential – and more interesting – than exploring stereo-selective metabolism. For the better part of a century, the consideration of chirality in drug metabolism was limited to academic study and/or to natural products, owing in no small part to the limits of separations chemistry. However, chirality has been earning ever-greater importance in drug discovery and development, such that most of the new molecular entities reaching the market in the first decades of the 21st century are single enantiomers, rather than the racemic mixtures (or achiral drugs) that dominated the latter half of the 20th century.

Stereo-selective metabolism has important impacts on scientific aspects such as pharmacokinetics, pharmacodynamics, drug safety, and bio-analytical chemistry; but also on regulatory, intellectual property, business and product development, and other important considerations. In this webinar you will view examples of typical stereo-selective metabolism reactions, potential drug-drug interactions, and bio-analytical chemistry approaches. A case study of stereo-selective metabolism and metabolite profiling will also be presented, with important questions to consider.

About the presenter:

James Schmidt brings nearly three decades of experience in xenobiotic metabolism and bio-analytical chemistry with private, government, and industrial laboratories to EAG Laboratories. His expertise lies in the intersection of experimental and analytical science, with special interests in agrochemical environmental fate and metabolism, and pharmaceutical small molecule metabolic stability, metabolite profiling and identification, chiral separations, and pharmacologically active metabolites. Schmidt is the author or co-author of several peer-reviewed posters and papers, as well as innumerable scientific reports to satisfy regulatory requirements of both the EPA and FDA. Prior to joining EAG Laboratories, Schmidt held positions with the USEPA’s Kerr Groundwater Research Laboratory, Sandoz Agro and Abbott Laboratories. Most recently, he served as Principal Scientist of Drug Metabolism and Pharmacokinetics at Lexicon Pharmaceuticals.

View Recording